Scientists from Pacific Northwest and Lawrence Berkeley National Laboratories showed that both dietary and supplementary sources of a common gut microbe or its main chemical product, lactic acid, led to better memory performance in mice.
Berkeley Lab’s Advanced Light Source X-ray facility has been recalled to action to support research related to COVID-19, the coronavirus disease that has already infected about 2 million people around the world.
One strategy to make biofuels more competitive is to make plants do some of the work themselves. Scientists can engineer plants to produce valuable chemical compounds, or bioproducts, as they grow. Then the bioproducts can be extracted from the plant and the remaining plant material can be converted into fuel. But one important part of this strategy has remained unclear — exactly how much of a particular bioproduct would plants need to make in order to make the process economically feasible?
Distinguished senior scientist Mina Bissell is one of five recipients of the 2020 Canada Gairdner International Award – an annual honor given to scientists who have contributed to transformative human health research.
A new material design has put the long-sought idea of artificial photosynthesis within reach.
Biomanufacturing – harnessing biological processes in cells and microbes to design and manufacture products – is revolutionizing how we make everything from futuristic consumer goods to sustainable fuels to breakthrough medicines. Every biomanufactured product can be traced back to discoveries in the lab, but translating that science into a real-world product can be tricky. Berkeley Lab is helping to move great ideas, like outdoor gear made from algae oil, from conception to commercialization.
An investigational cancer drug that targets tumors caused by mutations in the KRAS gene will be evaluated in phase 2 clinical trials, following promising safety and efficacy results in preliminary human studies and excellent results in animal studies. The drug, developed by Amgen and currently referred to as AMG 510, is the first therapy to reach clinical
Berkeley Lab’s Chris Mungall and Nomi Harris explain how agreeing on precise definitions of each rare disease can lead to more accurate diagnoses and better treatments, and share new evidence showing this endeavor is more important than ever.
A unique neural network tool is making it possible to accurately infer the interactions between the microbes that are present in a community and the metabolites they produce – a capability that will greatly advance research into the microbiomes in the environment and inside our bodies.
A new test agent can easily and efficiently detect the misfolded protein aggregates that cause devastating neurological diseases in blood samples. The technology could lead to early diagnosis of prion, Alzheimer’s, and Parkinson’s diseases for the first time.